AOTI, Inc. reported its final results for the year ended December 31, 2025, highlighting a 14.0% revenue growth to $66.5 million despite challenges in the US healthcare market. The company achieved meaningful operational progress, strengthening its core business and capabilities. Key financial highlights include a 14.0% revenue increase, a 162% rise in EBITDA to $7.5 million, and a profit before tax of $3.0 million. Operationally, AOTI expanded its Medicaid Provider ID to 19 states, secured significant payer endorsements for its TWO2® therapy, and made progress in rolling out Eyes on the Wound™. The company faced reimbursement issues in Arizona, leading to a decision to cease treating new Medicaid patients there from April 1, 2026. AOTI expects low single-digit revenue growth in 2026, with adjusted EBITDA margins in the high single digits, and remains confident in its long-term growth prospects, particularly with the anticipated CMS local coverage determination for TWO2®.
| Financial Metric | 2024 | 2025 | Change |
|---|---|---|---|
| Revenue | $58,359,000 | $66,537,000 | +14.0% |
| Adjusted EBITDA | $8,057,000 | $7,542,000 | -6.4% |
| EBITDA | $2,878,000 | $7,542,000 | +162% |
| Profit / (Loss) before tax | ($945,000) | $3,048,000 | n.m. |
| (Net Debt) / Net Cash | $858,000 | ($6,536,000) | n.m. |